SYRS vs. SGMT, AMLX, BPTS, ANVS, VTGN, IXHL, IMAB, RGLS, KPTI, and CRVO
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Sagimet Biosciences (SGMT), Amylyx Pharmaceuticals (AMLX), Biophytis (BPTS), Annovis Bio (ANVS), Vistagen Therapeutics (VTGN), Incannex Healthcare (IXHL), I-Mab (IMAB), Regulus Therapeutics (RGLS), Karyopharm Therapeutics (KPTI), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
Syros Pharmaceuticals (NASDAQ:SYRS) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.
91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 10.5% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Syros Pharmaceuticals presently has a consensus target price of $14.33, indicating a potential upside of 184.39%. Sagimet Biosciences has a consensus target price of $41.50, indicating a potential upside of 914.67%. Given Sagimet Biosciences' higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Syros Pharmaceuticals.
Syros Pharmaceuticals received 349 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 63.94% of users gave Syros Pharmaceuticals an outperform vote.
Sagimet Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals.
In the previous week, Syros Pharmaceuticals and Syros Pharmaceuticals both had 2 articles in the media. Sagimet Biosciences' average media sentiment score of 0.67 beat Syros Pharmaceuticals' score of -0.09 indicating that Sagimet Biosciences is being referred to more favorably in the news media.
Sagimet Biosciences has a net margin of 0.00% compared to Syros Pharmaceuticals' net margin of -1,656.34%. Sagimet Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.
Summary
Sagimet Biosciences beats Syros Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
